McKinsey & Company has agreed to pay $650 million to settle a US Department of Justice investigation into its work advising Purdue Pharma on how to boost OxyContin sales.
Al Jazeera reports that the consulting firm entered a five-year deferred prosecution agreement in federal court in Abingdon, Virginia, to resolve criminal charges tied to its role in the opioid crisis. Prosecutors said McKinsey advised Purdue on measures to “turbocharge” sales of the painkiller, and the company was charged with conspiring to misbrand a drug and obstruct justice.
The deal is notable because it goes beyond a routine financial settlement. It is part of a rare corporate criminal prosecution and includes compliance obligations that will extend over several years. According to the source, McKinsey must improve its internal practices to detect illegal activity and submit to oversight from the Justice Department and the HHS inspector general’s office.
The article also says McKinsey agreed to resolve a related civil investigation involving alleged False Claims Act violations and to enter a corporate integrity agreement. That widens the settlement beyond the criminal case itself and suggests regulators were pressing on multiple fronts.
A former senior partner, Martin Elling, also agreed to plead guilty to obstruction of justice for destroying records tied to McKinsey’s work for Purdue. The source says the court papers describe deleted documents and reminder emails sent to himself before the destruction. That detail underscores how document handling became part of the case against the firm.
McKinsey’s public statement in the report expresses regret for its past client service to Purdue and for the actions of the former partner. But the company still maintained that none of its settlements contains an admission of liability or wrongdoing. That distinction matters because many large corporate resolutions are structured to end litigation without a formal acknowledgment of fault.
The settlement is also part of a much longer legal history. Purdue pleaded guilty in 2020 to charges related to misleading conduct over prescription painkillers, and the company remains involved in bankruptcy mediation over a multibillion-dollar settlement. McKinsey previously reached other agreements totaling nearly $1 billion tied to lawsuits and legal actions over the opioid epidemic.
The broader significance is that one of the world’s best-known consulting firms is still paying for work done years ago to help fuel opioid sales. The case shows how consultants, manufacturers and regulators remain entangled in the aftermath of the epidemic, with financial penalties, oversight and reputation damage continuing long after the original sales push.
